Press releases
-
-
-
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
-
-
-
-
-
-
-
-
-
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
-
-
-
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
-
-
Internal link ProQR Announces Results for the Third Quarter of 2017
-
-
-
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
-
-
Internal link ProQR to Present at EuroTIDES Conference
-
Internal link ProQR Announces Management Change and Key Promotions
-
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
-